Gooderham, Melinda, Lynda Spelman, Shinichi Imafuku, Marco Romanelli, Joseph F. Merola, April W. Armstrong, Elizabeth Colston, Subhashis Banerjee, Thomas Scharnitz, and Andrew Blauvelt. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 7, no. 4 (July 17, 2023): s219. Accessed July 16, 2024.